Untitled

Abstract

Cefpodoxime proxetil is an oral antibiotic belonging to 3 rd generation Cephalosporin category. It has shown its antibiotic activity against both Gram positive and Gram-negative bacteria and has high stability in the presence of β-lactamase except Enterococci species. The drug has found its effectiveness in pediatric patients in treating respiratory tract infections. At the present time the most familiar form in which cefpodoxime proxitel is delivered is either oral tablet form or for pediatrics oral dry syrup form. The oral dry syrup form has to be administered twice or thrice a day in order to meet the required dosage regimen. Developing the sustained release formulation for cefpodoxime proxetil probably niosomal suspension can be effective in reducing the dosing frequency along with sustained release and targeted drug delivery. Niosomal suspensions are suspended form of niosomes in an aqueous phase to form liquid dosage form it is called niosomal suspension. It is a potential drug carrier for delivery of drugs orally in liquid form. The niosomal suspensions allow the targeted drug delivery with controlled/sustained release and lead to reduced dose frequency with improved bioavailability and higher therapeutic effectiveness. This could make the formulation most suitable with lesser side effects and higher patient compliance.